Global Respiratory Antiviral Drugs Market, By Disease Type (Pneumonia, Influenza, Bronchiolitis, Upper Respiratory Tract Infection, Others), Drug Class (Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors, Others), Route of Administration (Oral, Parenteral, Others), Type (Branded, Generic), Age Group (Pediatric, Adult, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The number of viral respiratory infections in people has increased dramatically. As a result of the rising number of medical visits and hospitalizations, the community's costs have climbed significantly. Among 200 viral respiratory pathogens, influenza and respiratory syncytial viruses (RSVs) are the most important viral pathogens. Antiviral medications are crucial in the prevention and treatment of various illnesses. Antiviral therapeutic drugs have traditionally been utilized as a supplement to immunization in the prevention of influenza in the aged population. For the treatment of respiratory viral infections, there are a few classes of authorized medicines. Nucleoside analogues, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors are only a few examples. Amantadine, Oseltamivir, Rimantadine, Ribavirin and Zanamivir are some of the most commonly prescribed antiviral medicines.
Data Bridge Market Research analyses that the respiratory antiviral drugs market was valued at USD 54.4 billion in 2021 and is expected to reach USD 78.02 billion by 2029, registering a CAGR of 4.61% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Pneumonia, Influenza, Bronchiolitis, Upper Respiratory Tract Infection, Others), Drug Class (Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors, Others), Route of Administration (Oral, Parenteral, Others), Type (Branded, Generic), Age Group (Pediatric, Adult, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Amneal Pharmaceuticals LLC. (US), AbbVie Inc. (US), Dr. Reddy's Laboratories Ltd. (India), Zydus Cadila (India), Johnson & Johnson Private Limited (US), Alembic Pharmaceuticals Limited (India), Lupin (India), Gilead Sciences, Inc. (US), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Aurobindo Pharma (India), Hetero (India), Teva Pharmaceutical Industries Ltd. (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Antiviral drugs are medicines used to treat viral illnesses, including HIV, hepatitis, herpes, and influenza. Vaccines are used to give antiviral medications. Antiviral medications are also used for specific viral infections, except for a handful that work against a wide spectrum of viruses. Protease inhibitors, reverse transcriptase inhibitors (NRTIs and NNRTIs), neuraminidase inhibitors, and DNA polymerase inhibitors are forms of antiviral drugs available in the market.
Respiratory Antiviral Drugs Market Dynamics
Drivers
- Rise in the prevalence of respiratory viral diseases
The surging prevalence of respiratory viral illnesses such as influenza, bronchiolitis, and others is a major factor driving the respiratory antiviral drugs market's growth rate during the forecast period of 2022-2029. Flu incidence and prevalence are steadily rising over the world. Every year, the flu affects between 5% and 20% of the population in the United States, according to the CDC. In addition, an estimated 200,000 persons are hospitalized in the United States each year owing to flu illness, with 36,000 of them succumbing to flu complications.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of respiratory antiviral drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Increase in the prevalence rate of viral infections and respiratory syncytial virus epidemics
Virus infections and respiratory syncytial virus outbreaks have increased dramatically in recent years, which can be ascribed to changing environmental conditions. Antiviral drugs diminish the capacity of viruses to transmit from cell to cell or person to person while also reducing the length of flu symptoms. Antiviral drugs are prescribed to treat and prevent influenza-like symptoms, viral pneumonia, and respiratory problems. Oseltamivir phosphate (Tamiflu), zanamivir (Relenza), and baloxavir are three of the most commonly prescribed antiviral medications by the Centers for Disease Control and Prevention (CDC) to treat seasonal flu. Hence, the rising prevalence rate of viral infections and respiratory syncytial virus epidemics is expected to enhance the market's growth rate.
Furthermore, the surging geriatric population and sedentary lifestyle of people, including high addiction of smoking will result in the expansion of respiratory antiviral drugs market. Along with this, favorable reimbursement policies will enhance the market's growth rate.
Opportunities
- Increasing number of research and development activities
The market's growth is fueled by an increase in the number of research and development activities. Treatments for respiratory syncytial virus (RSV) infection have shown to be beneficial in the treatment of bronchiolitis. For instance, Ark Biosciences, a biotech company focusing on therapies for viral infections and respiratory disorders, recently announced the phase 2 proof-of-concept study for Ziresovir (AK0529), an antiviral drug, was completed successfully. Bronchiolitis has killed hundreds of thousands of people globally, mostly children under the age of five. As a result, businesses in the respiratory antiviral treatment market are bolstering their research capacity in order to create treatments for infant bronchiolitis. This will provide beneficial opportunities for the respiratory antiviral drugs market growth.
Moreover, the market's growth is fueled by an increase in the number of product launches and emerging new markets. These factors will provide beneficial opportunities for the respiratory antiviral drugs market growth.
Restraints/Challenges
On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The shortage of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the respiratory antiviral drugs market. Additionally, a lack of awareness among people and the availability of generic medications will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This respiratory antiviral drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the respiratory antiviral drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Respiratory antiviral drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Respiratory Antiviral Drugs Market
The market for antiviral medications is classified into coronavirus infection, influenza, herpes simplex virus (HSV), hepatitis and other indications. Infectious viruses such as SARS COV-2, Ebola, swine flu, and Zika virus are becoming more common, increasing the demand for effective antiviral medications. In 2021, the Coronavirus infection sector had a market share of over 17% and is expected to increase significantly in the near future. The occurrence of the COVID-19 pandemic, which resulted in a global spike in the number of patients, has provided the segment with unparalleled growth potential.
Furthermore, the respiratory antiviral drugs market is anticipated to rise due to the significant presence of industry participants focused on research and development activities and product launches to battle COVID-19 infection. The US Food and Drug Administration granted Merck and Ridgeback Biotherapeutics emergency use authorization for molnupiravir in December 2021. (FDA). Expanded production and commercialization of these pharmaceuticals to serve a large patient population around the world has boosted category revenue tremendously. As a result, rising demand for antiviral drugs to treat coronavirus infection will boost total market growth.
Recent Development
- In December 2021, Pfizer had received the emergency use authorization from U.S. Food and (FDA) for Novel COVID-19 oral antiviral drug named PAXLOVID. PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is approved for emergency use in high-risk adults and children 12 years and older who weigh at least 40 kg.
- In December 2021, Cipla Limited received the Emergency Use Authorization (EUA) permission by Drug Controller General of India (DCGI) to launch oral antiviral COVID drug named Molnupiravir. Molnupiravir is the first oral antiviral authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to treat mild-to-moderate COVID-19 infection in people who are at high risk of developing severe disease.
Global Respiratory Antiviral Drugs Market Scope
The respiratory antiviral drugs market is segmented on the basis of disease type, drug class, type, age group, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Pneumonia
- Influenza
- Bronchiolitis
- Upper Respiratory Tract Infection
- Others
Drug Class
- Nucleoside Analogs
- Ribavirin
- Aciclovir
- Neuraminidase Inhibitors
- Oseltamivir
- Zanamivir
- Ion Channel Blockers
- Amantadine
- Rimantadine
- Fusion Protein Inhibitors
- Pavilizumab
- Others
Type
- Branded
- Generic
Age Group
- Pediatric
- Adult
- Geriatric
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Respiratory Antiviral Drugs Market Regional Analysis/Insights
The respiratory antiviral drugs market is analysed and market size insights and trends are provided by country, disease type, drug class, type, age group, route of administration, end-users and distribution channel as referenced above.
The countries covered in the respiratory antiviral drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the respiratory antiviral drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the prevalence of respiratory viral infection among infants and children and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to surging number of geriatric population in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Respiratory Antiviral Drugs Market Share Analysis
The respiratory antiviral drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to respiratory antiviral drugs market.
Some of the major players operating in the respiratory antiviral drugs market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (US)
- Amneal Pharmaceuticals LLC. (US)
- AbbVie Inc. (US)
- Dr. Reddy's Laboratories Ltd. (India)
- Zydus Cadila (India)
- Johnson & Johnson Private Limited (US)
- Alembic Pharmaceuticals Limited (India)
- Lupin (India)
- Gilead Sciences, Inc. (US)
- Cipla Inc. (US)
- Bausch Health Companies Inc. (Canada)
- Aurobindo Pharma (India)
- Hetero (India)
- Teva Pharmaceutical Industries Ltd. (Ireland)
SKU-